Andrew Stewart Plump Sells 19,651 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Andrew Stewart Plump sold 19,651 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $18.49, for a total transaction of $363,346.99. Following the completion of the transaction, the insider directly owned 261,656 shares in the company, valued at $4,838,019.44. This represents a 6.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Stewart Plump also recently made the following trade(s):

• On Monday, August 10th, Andrew Stewart Plump sold 165,393 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $17.10, for a total value of $2,828,220.30.

Takeda Pharmaceutical Stock Up 0.2%

NYSE:TAK opened at $18.17 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The stock has a 50 day moving average of $16.79 and a 200-day moving average of $17.18. The firm has a market capitalization of $58.22 billion, a PE ratio of 53.44 and a beta of -0.08. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.30. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The business had revenue of $7.50 billion for the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Analysts predict that Takeda Pharmaceutical Co. will post 1.54 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on TAK shares. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TAK. Capital Research Global Investors increased its position in Takeda Pharmaceutical by 0.6% in the 4th quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock valued at $210,259,000 after acquiring an additional 82,643 shares during the period. UBS Group AG boosted its position in Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after acquiring an additional 1,869,323 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in Takeda Pharmaceutical by 100.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after acquiring an additional 2,854,069 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Takeda Pharmaceutical by 15.0% in the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after purchasing an additional 692,404 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Takeda Pharmaceutical by 14.2% during the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after purchasing an additional 370,800 shares during the period. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.